Corrigendum: Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study
- DOI
- 10.3389/fonc.2022.889996
- Published
- 2022-06-07
- Container
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.3389/fonc.2022.889996,
title = {Corrigendum: Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study},
author = {Mark M. Awad and Yvan Le Bruchec and Brian Lu and Jason Ye and Julie Ann Miller and Patrick H. Lizotte and Megan E. Cavanaugh and Amanda J. Rode and Calin Dan Dumitru and Alexander Spira},
year = {2022},
journal = {Frontiers in Oncology},
doi = {10.3389/fonc.2022.889996},
url = {https://doi.org/10.3389/fonc.2022.889996}
}RIS
TY - JOUR TI - Corrigendum: Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study AU - Mark M. Awad AU - Yvan Le Bruchec AU - Brian Lu AU - Jason Ye AU - Julie Ann Miller AU - Patrick H. Lizotte AU - Megan E. Cavanaugh AU - Amanda J. Rode AU - Calin Dan Dumitru AU - Alexander Spira PY - 2022 JO - Frontiers in Oncology DO - 10.3389/fonc.2022.889996 UR - https://doi.org/10.3389/fonc.2022.889996 ER -
APA
Awad, M. M., Bruchec, Y. L., Lu, B., Ye, J., Miller, J. A., Lizotte, P. H., Cavanaugh, M. E., Rode, A. J., Dumitru, C. D., & Spira, A. (2022). Corrigendum: Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study. Frontiers in Oncology. https://doi.org/10.3389/fonc.2022.889996
Source records
- crossref · retrieved 2026-09-27T08:34:49.951Z